SAT0682 Prevalence of sarcopenia in patients with chronic inflammatory rheumatic diseases

Tournadre, Anne; Jaffeux, P.; Frayssac, Thomas; Fan, A.; Couderc, Marion; Dubost, Jean Jacques; Malochet‐Guinamand, Sandrine; Mathieu, S.; Tatar, Zuzana; Jourdy, J. C.; Soubrier, Martin

doi:10.1136/annrheumdis-2017-eular.5122

Cited by 5 publications

(15 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Demographics are shown in Table 3. Studies did not differentiate outcomes according to subtypes of psoriatic disease; however, five of the studies focused purely on psoriatic arthritis [18][19][20][21][22]. Only four studies [21][22][23][24] reported on the racial and ethnic groups of participants.…”

Section: Population Sampledmentioning

confidence: 99%

“…Only four studies [21][22][23][24] reported on the racial and ethnic groups of participants. A control group was assessed in 10 studies [18,20,21,23,[25][26][27][28][29][30], and this information was missing in another study [19]. None of the studies reported on socio-economic status, including employment or educational attainment of subjects.…”

Section: Population Sampledmentioning

confidence: 99%

“…Moreover, not all studies found that these changes were correlated to either skin or joint disease activity [11,19,35,36]. Three studies focused on muscle mass and reported levels of sarcopenia [18,21,22]. Aguiar et al evaluated muscle mass by way of a muscle mass index (MMI: muscle/height 2 ) and demonstrated reductions for spondyloarthritis with no significant variation between psoriatic arthritis and ankylosing spondylitis patients.…”

Section: Plos Onementioning

confidence: 99%

“…Six of the studies, whilst identifying as case-control, were reassigned as cross-sectional design on account of their methodology [22,24,36,[38][39][40]. Nine studies did not include a control group [18,20,21,23,[25][26][27][28][29]. Several studies did not fully specify how their participants were recruited [21,26,29,31] and there was uncertainty about this information from an additional four studies [11,18,20,28].…”

Section: Assessment Of Biasmentioning

confidence: 99%

“…Nine studies did not include a control group [18,20,21,23,[25][26][27][28][29]. Several studies did not fully specify how their participants were recruited [21,26,29,31] and there was uncertainty about this information from an additional four studies [11,18,20,28]. The sample size was small (< 40) for a number of studies [28,31,33,38].…”

Section: Assessment Of Biasmentioning

confidence: 99%

See 4 more Smart Citations

Psoriatic disease and body composition: A systematic review and narrative synthesis

et al. 2020

View full text Add to dashboard Cite

Background Obesity is a leading comorbidity in psoriatic disease, including both psoriasis (PsO) and psoriatic arthritis (PsA), and is associated with adverse metabolic and cardiovascular (CV) outcomes. Anthropometric parameters, such as weight, body mass index (BMI) and waist-tohip ratio, have been extensively reported in psoriatic disease. However, the associations of body composition and fat distribution with psoriasis have not yet been fully defined. Objectives To identify whether patients with psoriatic disease, including psoriatic arthritis, have altered body composition compared with the general population, and to review existing modalities for the assessment of body composition. Methods Electronic searches of the literature were conducted in PubMed, Medline (Ovid ®), Embase (Ovid ®), Cochrane Central Register of Controlled Trials (CENTRAL) and Google Scholar. Titles and abstracts were reviewed by two authors independently against a set of prespecified inclusion/exclusion criteria. The research question was answered with a systematic literature review and results were summarized narratively. Results Twenty-five full text articles met the inclusion criteria and were included in the final narrative analysis. The studies were of heterogeneous design and used a range of objective measures to assess body composition, including simple anthropometric measures, bioimpedance analysis (BIA), dual energy X-ray absorptiometry (DXA) and computed tomography (CT). Few studies met all the quality assessment criteria. Clinical heterogeneity prevented meta-analysis.

show abstract

Section: Population Sampledmentioning

confidence: 99%

Section: Population Sampledmentioning

confidence: 99%

Section: Plos Onementioning

confidence: 99%

Section: Assessment Of Biasmentioning

confidence: 99%

Section: Assessment Of Biasmentioning

confidence: 99%

See 3 more Smart Citations

Psoriatic disease and body composition: A systematic review and narrative synthesis

et al. 2020

View full text Add to dashboard Cite

show abstract

Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions

et al. 2021

View full text Add to dashboard Cite

Introduction Sarcopenia is defined by a loss of muscle mass and function associated with mortality, decreased physical performance, falls, and disability. Since chronic inflammation and decreased physical activity are risk factors for developing sarcopenia, it is critical to assess the role of sarcopenia in immune-mediated rheumatic diseases (IMRDs). Moreover, nutritional interventions are emerging as key modifiable and affordable options to improve physical performance in sarcopenia. Objective The aim of this review is to critically summarize current information on the evidence linking nutritional interventions and sarcopenia in IMRDs. Methods The search and selection of articles was performed in Medline, Dimensions.ai, Google Scholar, Cochrane Library, Epistemonikos, and Trip Database. The results were clustered into three areas: sarcopenia and IMRDs, sarcopenia and biological disease-modifying antirheumatic drugs (bDMARDs), and nutritional interventions for sarcopenia. Findings Several cross-sectional studies have shown a higher prevalence of sarcopenia in IMRDs, such as rheumatoid arthritis. Although not fully established, evidence linking sarcopenia and other IMRDs (ankylosing spondylitis and systemic sclerosis) has been also described. For secondary sarcopenia prevention and treatment, bDMARDs’ administration proved efficacy in patients with rheumatoid arthritis. Furthermore, there is growing evidence linking nutrition to the prevention and treatment of sarcopenia. Evidence linking unfavourable results in nutritional risk assessment, insufficient intake of protein, vitamin D, antioxidant nutrients, and long-chain polyunsaturated fatty acids and sarcopenia have been reported. Conclusion Given that sarcopenia and IMRDs have strong links, further research is needed to improve patient care.

show abstract

Psoriatic disease and body composition: a systematic review of the literature

Blake

Gullick

Hutchinson

et al. 2020

Preprint

View full text Add to dashboard Cite

Background. Obesity is a leading comorbidity in psoriatic disease, including both psoriasis (Pso) and psoriatic arthritis (PsA), and is associated with adverse metabolic and cardiovascular (CV) outcomes. Anthropometric parameters, such as weight, body mass index (BMI) and waist-to-hip ratio, have been extensively reported in psoriatic disease. However, the associations of body composition and fat distribution with psoriasis have not been fully defined. Objectives. To identify whether patients with psoriatic disease, including psoriatic arthritis, have altered body composition compared with the general population, and to review existing modalities for the assessment of body composition. Methods. Electronic searches of the literature were conducted in PubMed, Medline (Ovid), Embase (Ovid), Cochrane Central Register and Google Scholar. Titles and abstracts were reviewed by two authors independently against a set of prespecified inclusion/exclusion criteria. Results. Twenty-five full text articles met the inclusion criteria and were included in the final narrative analysis. The studies were of heterogeneous design and used a range of objective measures to assess body composition, including simple anthropometric measures, bioimpedance analysis (BIA), dual energy X-ray absorptiometry (DXA) and computed tomography (CT). Few studies met all the quality assessment criteria. Conclusions. Patients with psoriatic disease reveal defined body composition changes that are independent of obesity and the customary metabolic syndrome, including higher overall body fat, visceral fat and sarcopenia. These findings emphasize that patients with psoriatic disease should be screened for abnormal adipose effects beyond their weight and body mass index (BMI). Our findings show that the last decade has seen an exciting expansion of research interest in the development and validation of new modalities for the assessment of body composition. There is no consensus on the optimal assessment method of body composition for this diverse group, hence there is a need for validation of existing modalities and standardization of assessment tools.

show abstract

SAT0682 Prevalence of sarcopenia in patients with chronic inflammatory rheumatic diseases

Cited by 5 publications

References 0 publications

Psoriatic disease and body composition: A systematic review and narrative synthesis

Psoriatic disease and body composition: A systematic review and narrative synthesis

Sarcopenia, immune-mediated rheumatic diseases, and nutritional interventions

Psoriatic disease and body composition: a systematic review of the literature

Contact Info

Product

Resources

About